Month 24 Clinical Trial Results in Dry AMD Patients

Eleanora Lad, MD, PhD; and Victor Gonzalez, MD

Show Description +

Eleanora Lad, MD, PhD, and Victor Gonzalez, MD, discuss key outcomes from the LIGHTSITE III clinical trial evaluating photobiomodulation therapy with the Valeda® Light Delivery System. Dr. Lad highlights that the study met its primary endpoint, showing a statistically significant improvement in BCVA. Dr. Gonzalez emphasizes the reduction in new geographic atrophy development, suggesting Valeda’s potential in managing dry AMD as a chronic, progressive disease.

Posted: 5/16/2025

Keywords:

LumiThera

•

Valeda

•

Dry age-related macular degeneration (Dry AMD)

•

Age-Related Macular Degeneration (AMD)

•

Clinical Trials

•

Photobiomodulation

•

bcva

•

Geographic Atrophy (GA)

Up Next

Promising Anatomic Outcomes from LIGHTSITE III Trial

Diana V. Do, MD, and Glenn J. Jaffe, MD

Valeda Demonstrates Vision Improvement in Patients with Dry AMD

Diana V. Do, MD, and Glenn J. Jaffe, MD

Safety and Efficacy Results from LIGHTSITE III Trial for Dry AMD

David S. Boyer, MD; and Marion R. Munk, MD, PhD

Valeda Mechanisms of Action – U.S.

Back to All Videos